Over time, more promising findings lengthen the list of potential uses
Unlike earlier medications such as semaglutide or tirzepatide, which act on one or two receptors, retatrutides triple mechanism may make it more effective for people struggling with obesity or insulin resistance
Heres what we know and dont know: Most cases were described as mild and did not lead to stopping the drug Its not seen with semaglutide or tirzepatide it may be related to glucagon receptor activation, but this isnt confirmed The Phase 2 trial did note altered or enhanced skin sensation at lower rates, so it may not be entirely new just more apparent at scale It needs investigation across the remaining 7 Phase 3 trials reporting in 2026 Is it a dealbreaker
These medications should only be taken when given by a healthcare professional, and they may not be suitable for everyone
Clinical trial entry usually depends on factors such as BMI, medical history, existing health conditions, current medication and location
It stimulates your body to make more insulin after you eat, prevents your liver from releasing stored sugar, and slows the movement of food through your body